Key statistics
As of last trade, Verrica Pharmaceuticals Inc (1NE:FRA) traded at 0.9305, 44.71% above the 52 week low of 0.643 set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9305 |
---|---|
High | 0.9305 |
Low | 0.9305 |
Bid | 0.948 |
Offer | 0.956 |
Previous close | 0.72 |
Average volume | 73.89 |
---|---|
Shares outstanding | 45.60m |
Free float | 23.83m |
P/E (TTM) | -- |
Market cap | 45.14m USD |
EPS (TTM) | -1.83 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:10 GMT.
More ▼
- Verrica Announces Pricing of $42.0 Million Public Offering
- Verrica Announces Proposed Public Offering
- Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
- Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
- Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
- Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
More ▼